‘Anti-VEGFs Have Reached Their Limit:’ EyeBio Targets New Pathway For Eye Therapies

Potential First-In-Class Wnt Agonist

 
• By Andrew McConaghie
  
Around half of patients taking anti-VEGF therapies still have fluid on the eye, compromising their vision. • Source: Image archive
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip